

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- ✓ • BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**







Figure 2A



G418

Figure 2B





Promoterless	CMV Promoter	Integration Site
<u>Luc Activity</u>	<u>Luc Activity</u>	<u>Interpretation</u>
High	High	Nearby strong promoter
Low	Low	Nearby silencing element
Low	High	"Neutral" site

Figure 3

Figure 4A




Figure 4B





Figure 4C






Figure 5




Figure 6




Figure 7A




Figure 7B




Figure 8




Figure 9A




Figure 9B




Figure 10




Figure 11




Figure 12




Figure 13.





Figure 14.



MLL Leukemia Cell Line TS(4;11) Treated with FLT3 Inhibitor PKC-412




FIG. 15

MLL Leukemia Treated with FLT3 Inhibitor PKC-412




FIG. 16

Validation of FLT3 as a Target in MLL




FIG. 17

Validation of FLT3 as a Target in MLL Utilizing shRNA and *In Vivo* Imaging



FIG. 18

ADW Effects in an Orthotopic Model of Multiple Myeloma (MM1S)




FIG. 19

ADW Effects in an Orthotopic Model of Multiple Myeloma




FIG. 20

Efficacy of AMN107 Against 32D/p210-Luc Cells *In Vivo*




FIG. 21

Quantitation of AMN107 Effects Against 32D/p210-Luc Cells *In Vivo*




FIG. 22

Orthotopic Brain Tumor Model




FIG. 23

In Vivo Efficacy of AMD-3100




FIG. 24

In Vivo Imaging of Transcriptional Pathway Activity




FIG. 25

CXCR4 Inhibition with AMD3100 Attenuates ERK1/2 Signalling *In Vivo*




FIG. 26

In Vivo Imaging of Hypoxia-Inducible Reporter Activity

Cell line: HepG2 Epo-Luc c.1
Innoculum: 3 million cells
Time: 48 hrs after implantation



FIG. 27